Despite the competitive threat posed by Eli Lilly’s acquisition of Scorpion Therapeutics’ STX-478, which has shown promising efficacy in several cancer types, Relay Therapeutics’ RLY-2608 ...

Eli Lilly (NYSE:LLY) is in advanced discussions to purchase cancer-focused biotech Scorpion Therapeutics for as much as $2.5 billion. A deal is likely to be reached in the coming days ahead of the ...

Sanofi S.A. Part Cert 0.02% €8.03M ...

Protective Relay Training—This 12-hour live online instructor-led training course provides a comprehensive understanding of industrial, commercial, and institutional power system protection. Relay ...